[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE131730T1 - Nukleosidanalogen enthaltende antiviren- zubereitungen - Google Patents

Nukleosidanalogen enthaltende antiviren- zubereitungen

Info

Publication number
ATE131730T1
ATE131730T1 AT92201328T AT92201328T ATE131730T1 AT E131730 T1 ATE131730 T1 AT E131730T1 AT 92201328 T AT92201328 T AT 92201328T AT 92201328 T AT92201328 T AT 92201328T AT E131730 T1 ATE131730 T1 AT E131730T1
Authority
AT
Austria
Prior art keywords
preparations containing
nucleoside analogues
virus preparations
containing nucleoside
virus
Prior art date
Application number
AT92201328T
Other languages
English (en)
Inventor
Janet Mary Cameron
Nicholas Cammack
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE131730(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919110624A external-priority patent/GB9110624D0/en
Priority claimed from GB919121381A external-priority patent/GB9121381D0/en
Priority claimed from GB919123581A external-priority patent/GB9123581D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE131730T1 publication Critical patent/ATE131730T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92201328T 1991-05-16 1992-05-11 Nukleosidanalogen enthaltende antiviren- zubereitungen ATE131730T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919110624A GB9110624D0 (en) 1991-05-16 1991-05-16 Combinations
GB919121381A GB9121381D0 (en) 1991-10-08 1991-10-08 Combinations
GB919123581A GB9123581D0 (en) 1991-11-06 1991-11-06 Combinations

Publications (1)

Publication Number Publication Date
ATE131730T1 true ATE131730T1 (de) 1996-01-15

Family

ID=27265656

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92201328T ATE131730T1 (de) 1991-05-16 1992-05-11 Nukleosidanalogen enthaltende antiviren- zubereitungen

Country Status (25)

Country Link
US (2) US5627186A (de)
EP (1) EP0513917B2 (de)
JP (1) JP2868671B2 (de)
KR (1) KR100246687B1 (de)
CN (1) CN1045961C (de)
AT (1) ATE131730T1 (de)
AU (2) AU1787492A (de)
CA (1) CA2068790C (de)
CZ (1) CZ285232B6 (de)
DE (2) DE69206876T3 (de)
DK (1) DK0513917T4 (de)
ES (1) ES2083668T5 (de)
GR (1) GR3018915T3 (de)
HK (1) HK78897A (de)
IE (1) IE73261B1 (de)
IL (1) IL101883A (de)
LU (1) LU90234I2 (de)
MX (1) MX9202279A (de)
NL (1) NL980018I2 (de)
NO (2) NO301690B1 (de)
NZ (2) NZ299240A (de)
OA (1) OA10058A (de)
SK (1) SK279262B6 (de)
TW (1) TW273550B (de)
WO (1) WO1992020344A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
EP0938321B1 (de) 1996-06-25 2004-01-14 Glaxo Group Limited Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
CA2298681C (en) 1997-08-08 2008-07-08 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
CN1391486A (zh) 1999-07-22 2003-01-15 新生物公司 治疗对治疗有抗性的肿瘤的方法
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
CA2505130C (en) * 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
CN105596356A (zh) * 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
JP4482883B2 (ja) 2003-05-22 2010-06-16 リードケミカル株式会社 抗ウイルス作用を有する化合物およびその配合剤
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP1975923B1 (de) * 2007-03-28 2016-04-27 Nuance Communications, Inc. Mehrsprachige nicht-muttersprachliche Spracherkennung
EP2435052B1 (de) 2009-05-27 2015-07-15 Hetero Research Foundation Feste orale lamivudin-darreichgungsformen mit isomalt
EP2579892A2 (de) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutische immunisierung von hiv-infizierten personen mit stabiler antiretroviraler behandlung
MX2014010337A (es) 2012-03-05 2014-11-14 Cipla Ltd Combinaciones farmaceuticas antirretrovirales que comprenden lamivudina, festinavir y nevirapina.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
GB8717955D0 (en) * 1987-07-29 1987-09-03 Fujisawa Pharmaceutical Co Prevention & treatment of aids
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
WO1989009056A1 (en) * 1988-03-23 1989-10-05 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
JPH02504283A (ja) * 1988-03-23 1990-12-06 ニューヨーク　ユニバーシィティ 芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
DE68900926D1 (de) * 1988-09-28 1992-04-09 Sigma Tau Ind Farmaceuti Pharmazeutische zubereitung, die zidovudin und inosiplex oder bestandteile davon enthaelt, fuer die behandlung von aids-verwandten syndromen.
EP0374096B1 (de) * 1988-12-14 1992-12-02 Ciba-Geigy Ag 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv History of tetrahydroimidazo [1,4] benzodiazepine-2-thione, their preparation and pharmaceutical preparations containing them
NZ232912A (en) * 1989-03-17 1992-06-25 Oncogen Ltd Lp Synergistic composition of nucleoside derivatives for inhibiting hiv
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) † 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
NO921947L (no) 1992-11-17
DE19875016I2 (de) 2004-07-01
ES2083668T3 (es) 1996-04-16
DK0513917T4 (da) 2001-06-25
NO301690B1 (no) 1997-12-01
IE73261B1 (en) 1997-05-21
DE69206876T2 (de) 1996-05-23
DE69206876T3 (de) 2004-08-12
EP0513917B1 (de) 1995-12-20
CA2068790C (en) 2005-06-07
JPH06234641A (ja) 1994-08-23
NL980018I1 (nl) 1998-07-01
US5859021A (en) 1999-01-12
CZ285232B6 (cs) 1999-06-16
NO921947D0 (no) 1992-05-15
US5627186A (en) 1997-05-06
LU90234I2 (fr) 1998-06-24
KR920021148A (ko) 1992-12-18
CN1068570A (zh) 1993-02-03
TW273550B (de) 1996-04-01
ES2083668T5 (es) 2001-06-16
NL980018I2 (nl) 1998-11-02
CA2068790A1 (en) 1992-11-17
SK119993A3 (en) 1994-04-06
IL101883A0 (en) 1992-12-30
AU1627992A (en) 1992-11-19
SK279262B6 (sk) 1998-08-05
KR100246687B1 (ko) 2000-04-01
NZ299240A (en) 2004-11-26
HK78897A (en) 1997-06-20
CZ242893A3 (en) 1994-07-13
JP2868671B2 (ja) 1999-03-10
WO1992020344A1 (en) 1992-11-26
CN1045961C (zh) 1999-10-27
NO1999018I1 (no) 1999-07-22
AU661307B2 (en) 1995-07-20
MX9202279A (es) 1992-11-01
OA10058A (en) 1996-10-14
DE69206876D1 (de) 1996-02-01
AU1787492A (en) 1992-12-30
NZ242754A (en) 1996-11-26
GR3018915T3 (en) 1996-05-31
DK0513917T3 (da) 1996-02-05
EP0513917A1 (de) 1992-11-19
EP0513917B2 (de) 2001-03-07
IL101883A (en) 1998-10-30
IE921566A1 (en) 1992-11-18

Similar Documents

Publication Publication Date Title
ATE131730T1 (de) Nukleosidanalogen enthaltende antiviren- zubereitungen
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
HK1015137A1 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha d-neuraminic acid
DK0388049T3 (da) Penciclovirderivater til behandling af hepatitis B infektioner
DE68900760D1 (de) Virushemmende nukleosidmischung.
YU221289A (en) Antivirus compounds
DK0728001T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 6-infektioner
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.
KR960021046A (ko) 카페익산을 포함하는 b형 간염 치료제